Achillion to Present at the 2017 JMP Securities Life Sciences Conference
15. Juni 2017 16:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., June 15, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion to Present at the Jefferies 2017 Global Healthcare Conference
05. Juni 2017 16:51 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., June 05, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the Achillion management team will present a corporate overview at...
Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs
04. Mai 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2017. For the first quarter of...
Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference
02. Mai 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 02, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
22. April 2017 03:00 ET
|
Achillion Pharmaceuticals, Inc.
AMSTERDAM, the Netherlands, April 22, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the presentation of updated results from the ongoing phase 2 ‘604 Study’...
Achillion Announces Initiation of Patient Dosing in Phase 2 Study of ACH-4471 for Paroxysmal Nocturnal Hemoglobinuria
06. April 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., April 06, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced initiation of patient dosing in a Phase 2 open-label study of ACH-4471,...
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors
21. März 2017 16:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., March 21, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent...
Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London
28. Februar 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
Three-year study commenced to include up to 400 patientsNatural history studies track course of a disease over time; can inform and support development and approval of new treatments for patientsC3...
Achillion Reports 2016 Fourth Quarter and Year-End Financial Results
23. Februar 2017 16:05 ET
|
Achillion Pharmaceuticals, Inc.
Complement factor D inhibitor program on track for initiation of ACH-4471 phase II trial for treatment-naïve PNH patients during the first half of 2017Expanding complement platform includes internally...
Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference
13. Februar 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...